Corcept’s ALS drug fails to improve function in Phase 2 study

It’s been a tough few months for Corcept Therapeutics. In October, the company’s lead pipeline candidate missed the primary endpoint in a Phase 3 Cushing’s syndrome trial. Now, its only neurology asset ...